Table 1. Ultrasonographic diagnoses, cytological diagnoses, and BRAF mutation analyses of 200 thyroid nodules according to final results.

	BRAF mutation analysis
	Negative (n = 119, 59.5%)	Positive (n = 81, 40.5%)
US diagnosis
Benign (n = 44, 22%)	NH (1), NSBN (41); (n = 42, 21%)	NH (1), NSBN (1); (n = 2, 1%)
Probably benign (n = 38, 19%)	NH (2), FA (2), NSBN (33); (n = 37, 18.5%)	PTC (1); (n = 1, 0.5%)
Indeterminate (n = 20, 10%)	PTC (1), FTC (1), FA (1), NSBN (9); (n = 12, 6%)	PTC (8); (n = 8, 4%)
Suspicious for malignancy (n = 57, 28.5%)	PTC (10), MTC (1), NH (1), NSBN (10); (n = 22, 11%)	PTC (35); (n = 35, 17.5%)
Malignant (n = 41, 20.5%)	PTC (5), MTC (1); (n = 6, 3%)	PTC (35); (n = 35, 17.5%)
Cytological diagnosis (Bethesda category)
I (n = 5, 2.5%)	PTC (1), NSBN (3); (n = 4, 2%)	PTC (1); (n = 1, 0.5%)
II (n = 99, 49.5%)	PTC (2), FTC (1), FA (3), NH (2), NSBN (84); (n = 92, 46%)	PTC (5), NH (1), NSBN (1); (n = 7, 3.5%)
III (n = 18, 9%)	PTC (3), NSBN (6); (n = 9, 4.5%)	PTC (9); (n = 9, 4.5%)
IV (n = 0, 0%)	0	0
V (n = 25, 12.5%)	PTC (3), NH (2); (n = 5, 2.5%)	PTC (20); (n = 20, 10%)
VI (n = 53, 26.5%)	PTC (7), MTC (2); (n = 9, 4.5%)	PTC (44); (n = 44, 22%)

Note.—Numbers in parentheses are prevalence of each item. US, ultrasonography; NH, nodular hyperplasia; NSBN, Non-surgical benign nodules, which were finally determined by repeated fine-needle aspiration cytology or fine-needle aspiration cytology and follow-up ultrasonographic findings. FA, follicular adenoma; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma.